▲ Peaking
Business
Lilly's Retatrutide Trounces Ozempic In Head-To-Head Study
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Retatrutide
18 trends tracked about this subject — the full history, oldest to newest below.
▲ Peaking
Business
Retatrutide beats Ozempic on weight loss, blood sugar control, study says
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
↓ Cooling
Business
Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly reports that its new drug, retatrutide, achieved more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
◼ Archived
Business
Someone Ran a Chemical Analysis of Bodega Retatrutide and Dear Lord
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Health
Triple-action weekly weight-loss drug reduces sleep apnea in two late-stage trials
An investigational triple-action weekly weight-loss drug significantly reduces obstructive sleep apnea severity in late-stage clinical trials.
◼ Archived
Business
Tests of Unapproved Weight- Loss Drug Reveal Its Dangers
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
The Most Powerful Weight Loss Drug Yet Isn’t Approved, but Its Black Market May Already Be Turning Deadly
Unapproved weight loss drug retatrutide faces a booming black market linked to multiple reported deaths and severe side effects.
◼ Archived
Health
Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame?
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
◼ Archived
Business
Lilly's retatrutide GLP-1 delivers average weight loss of 50 pounds
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data
Lilly positions its retatrutide drug combo for a next-generation obesity battle following full phase 3 study results.
◼ Archived
Business
Most powerful obesity drug yet: People lost up to 25% of weight in trial
Eli Lilly's experimental triple agonist drug retatrutide demonstrates significant weight loss and A1C reduction in recent clinical trials.
◼ Archived
Business
🔮 fades ✓
Eli Lilly is suing six companies over illegal sales of its unapproved weight loss drug
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly targets the illicit market for its unapproved obesity drug retatrutide through new legal actions.
◼ Archived
Health
🔮 fades ✓
Is 'Gym Penis' Real? Retatrutide Access Expanded; Vitamin D Fails Cancer Test
4 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 holds ✓
Eli Lilly to allow more patients to apply for special access to unapproved obesity drug
10 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
🔮 fades
Eli Lilly’s Anticipated Weight Loss Drug Helped People Lose 56 Pounds On Average
Eli Lilly's retatrutide shows significant weight loss results in Phase 3 trials, paving the way for a 2027 FDA approval filing.
◼ Archived
Business
🔮 fades
Eli Lilly’s Next-Generation Weight-Loss Shot Clears Another Hurdle
Eli Lilly targets a first-quarter 2027 FDA application for its next-generation obesity drug retatrutide.
◼ Archived
Business
🔮 fades
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is moving toward 2027 regulatory filings for retatrutide after successful Phase 3 obesity trials showing significant weight and A1C improvements.